Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.47 |
| ▸ | DRD3 | P35462 | 6/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27006987 | 0.86 | MEN1 (0.45) | GRM4KDM4EALDH1A1POLBSMYD3 | |
| SCHEMBL30425861 | 0.86 | SMYD3 (0.51) | GRM4KDM4EALDH1A1POLBSMYD3 | |
| SCHEMBL25131312 | 0.85 | KDM4E (0.56) | GRM4KDM4EALDH1A1DRD3MEN1 | |
| SCHEMBL30499299 | 0.85 | KDM4E (0.56) | GRM4KDM4EALDH1A1DRD3MEN1 | |
| SCHEMBL27006787 | 0.84 | ALDH1A1 (0.51) | GRM4KDM4EALDH1A1SMYD3DRD3 | |
| SCHEMBL27006916 | 0.83 | SMYD3 (0.45) | GRM4ALDH1A1SMYD3 | |
| SCHEMBL30499279 | 0.81 | KDM4E (0.64) | GRM4KDM4EALDH1A1 | |
| SCHEMBL27006913 | 0.81 | KDM4E (0.50) | GRM4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14495853 | 0.81 | KDM4E (0.64) | GRM4KDM4EALDH1A1 | |
| SCHEMBL30425758 | 0.81 | LMNA (0.43) | GRM4KDM4EALDH1A1POLBDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | GRM4 1956/4885KDM4E 474/4885ALDH1A1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.